| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC19A1 |
| Uniprot No | P41440 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 420-591aa |
| 氨基酸序列 | DVRGLGLPVRKQFQLYSVYFLILSIIYFLGAMLDGLRHCQRGHHPRQPPAQGLRSAAEEKAAQALSVQDKGLGGLQPAQSPPLSPEDSLGAVGPASLEQRQSDPYLAQAPAPQAAEFLSPVTTPSPCTLCSAQASGPEAADETCPQLAVHPPGVSKLGLQCLPSDGVQNVNQ |
| 预测分子量 | 25.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC19A1重组蛋白的参考文献示例(注：以下内容为示例性概括，部分文献信息可能为虚构，建议通过学术数据库核实具体文献)：
1. **文献名称**: *"Functional Characterization of Recombinant Human SLC19A1 Expressed in HEK293 Cells"*
**作者**: Deng, Y. et al.
**摘要**: 本研究在HEK293细胞中成功表达了重组人源SLC19A1蛋白，并验证其作为还原型叶酸转运体(RFC)的功能。通过放射性标记叶酸类似物的摄取实验，证实该蛋白具有pH依赖性，并对甲氨蝶呤(MTX)等抗肿瘤药物表现出高亲和力。
2. **文献名称**: *"Purification and Structural Insights of SLC19A1 Recombinant Protein from E. coli"*
**作者**: Zhao, L. et al.
**摘要**: 研究利用大肠杆菌表达系统高效表达并纯化了SLC19A1重组蛋白，通过亲和层析和尺寸排阻色谱获得高纯度蛋白。进一步通过冷冻电镜技术解析了其跨膜结构域，揭示了关键氨基酸残基在底物识别中的作用。
3. **文献名称**: *"Role of SLC19A1 in Cellular Folate Transport: A Kinetic Study Using Recombinant Protein"*
**作者**: Smith, J.R. et al.
**摘要**: 通过体外重组SLC19A1蛋白的功能分析，量化了叶酸及其衍生物的转运动力学参数。研究发现，该蛋白的转运效率受膜电位调控，并确定了若干突变位点(如H128R)可显著降低底物结合能力。
4. **文献名称**: *"SLC19A1-Mediated Drug Resistance: Implications from Recombinant Protein Studies"*
**作者**: Garcia-Salcedo, J.A. et al.
**摘要**: 利用重组SLC19A1蛋白模型，探讨了肿瘤细胞对化疗药物(如5-氟尿嘧啶)的耐药机制。实验表明，蛋白表达水平与药物敏感性呈负相关，并发现某些抑制剂可竞争性阻断转运活性。
**建议**：以上文献信息为示例性质，实际文献可通过PubMed、Web of Science等平台以关键词“SLC19A1 recombinant protein”或“SLC19A1 expression/purification”检索。
**Background of SLC19A1 Recombinant Protein**
SLC19A1. also known as the reduced folate carrier 1 (RFC1), is a solute carrier family protein encoded by the *SLC19A1* gene. It functions as a transmembrane transporter, primarily facilitating the cellular uptake of reduced folates (e.g., tetrahydrofolate) and antifolate therapeutics, such as methotrexate, which are critical for nucleotide synthesis and one-carbon metabolism. Structurally, SLC19A1 is characterized by 12 transmembrane domains and is expressed ubiquitously, with higher levels in tissues like the liver, kidneys, and intestines.
Recombinant SLC19A1 protein is engineered using heterologous expression systems (e.g., mammalian or insect cell lines) to produce functional, purified protein for biochemical and pharmacological studies. This recombinant form retains the transporter’s native activity, enabling researchers to investigate its substrate specificity, kinetics, and interactions with drugs or genetic variants. Its production often involves affinity tag-based purification (e.g., His-tag) followed by validation via SDS-PAGE, Western blotting, or functional uptake assays.
SLC19A1 is of clinical relevance due to its role in modulating responses to antifolate chemotherapies and its association with diseases. Genetic polymorphisms in *SLC19A1* influence folate homeostasis and methotrexate efficacy/toxicity, impacting cancer and autoimmune disease treatments. Additionally, altered SLC19A1 expression has been linked to conditions like neural tube defects and mitochondrial dysfunction.
Research using recombinant SLC19A1 protein enhances understanding of transport mechanisms, drug resistance, and personalized therapeutic strategies. It also aids in screening novel substrates or inhibitors, contributing to drug development and precision medicine in oncology and beyond.
×
